MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced that it has achieved several key product development milestones in its rapidly growing Peripheral vascular business. These milestones include submission of the first Carotid Solution Pre-Market Approval (PMA) module to the U.S. Food and Drug Administration, and CE Mark for two key stent products – the Medtronic Complete SE iliac stent and the Medtronic Racer RX renal stent. Medtronic made the announcement today at the fourth annual VIVA™ 06 medical meeting in Las Vegas.
